Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study.

Background: The efficacy of intravenous (IV) ferric carboxymaltose (FCM) has been demonstrated in haemodialysis and non-dialysis studies, but evidence is lacking in patients undergoing peritoneal dialysis (PD).

Methods: This multicentre, retrospective study evaluated the effectiveness and safety of FCM in patients on PD over 12 months. We retrospectively reviewed the electronic medical records of PD patients who initiated FCM treatment between 2014 and 2017 across seven Spanish centres.

How should we analyze and present mortality in our patients?: A multicentre GCDP experience.

Introduction: There are different strategies to analyse mortality in peritoneal dialysis (PD) with different definitions for case, event, time at risk, and statistical tests. A common method for the different registries would enable proper comparison to better understand the actual differences in mortality of our patients.

Methods: We review and describe the analysis strategies of regional, national and international registries.

Peritoneal dialysis (PD) is a successful treatment after complete haemodialysis (HD) blood access failure complicated with superior vena cava syndrome (SVCS).

SVCS constitutes a serious clinical problem and often represents a definitive loss of vascular access for haemodialysis (HD). The patients must suffer numerous interventions in order to obtain a permanent vascular access for HD. Treatment of SVCS requires endovascular intervention or complex surgical revascularization.